<DOC>
	<DOCNO>NCT00941798</DOCNO>
	<brief_summary>Study CQMF149A2210 evaluate safety QMF149 Twisthaler® 500/400 μg , fix dose combination indacaterol 500 μg , daily β2 agonist , mometasone furoate 400 μg , inhale corticosteroid ( ICS ) approve use treatment asthma . The objective safety trial assess effect treatment incidence serious asthma exacerbation , define asthma related hospitalization and/or intubation and/or death . This event driven trial .</brief_summary>
	<brief_title>Safety QMF149 Twisthaler® Adolescent Adult Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Patients document diagnosis persistent asthma currently treat qualified treatment ICS longacting beta2agonist ( LABA ) combination Patients demonstrate increase force expiration volume 1 second ( FEV1 ) ≥ 12 % ≥ 200 mLs within 30 minute administration shortacting beta2agonist ( SABA ) Patients FEV1 ≥ 50 % predict normal Patients previous diagnosis chronic obstructive pulmonary disease ( COPD ) Patients asthma attack/exacerbation require hospitalization/emergency room visit respiratory tract infection within 1 month prior randomization Patients ever require ventilator support respiratory failure Patients diabetes Type I uncontrolled diabetes Type II Patients concomitant pulmonary disease Patients certain cardiovascular comorbid condition Patients significant medical condition might compromise patient safety , interfere evaluation preclude completion study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>LABA</keyword>
	<keyword>Safety</keyword>
</DOC>